The clinical impact of testing for biomarkers in gastric cancer patients: a real‐world cohort
Histopathology · 2023
DOI: 10.1111/his.14869 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von Karen van der Sluis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Stomach Neoplasms, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Dutch Cancer Society, Dutch Ministry of Health, Welfare and Sport, KWF Kankerbestrijding.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background and aims In gastric cancer (GC), HER2 was the first biomarker for guided therapy registered for clinical use. Considering the recent approvals of immune check‐point blockade (ICB) in gastro‐oesophageal cancers, testing for mismatch repair deficiency (dMMR), Epstein–Barr virus (EBV) and PD‐L1 combined positive score (CPS) is becoming increasingly important. Here we describe a real‐world cohort on biomarker assessment in GC patients.
Methods
Patients diagnosed with GC between 2017 and 2021 were included. Biomarker results were retrieved from electronic patient files. PD‐L1 CPS was determined retrospectively on dMMR and EBV‐positive (EBV+) tumours. Data on genomic sequencing were analysed separately.
Results
Of 363 patients identified, 45% had metastatic disease. In 335 patients (92%) at least one biomarker was tested. The prevalence of HER2+, dMMR and EBV+ tumours was 10% (32 of 319), 7% (20 of 294) and 1% (three of 235), respectively. Of the dMMR and EBV+ tumours, 95% had a PD‐L1 CPS ≥ 5. Therapeutic strategy was adjusted in 31 of 55 patients and consisted of anti‐HER2 therapies as well as ICB in clinical trials. Genomic alterations were found in 44 of 60 tested patients. TP53 (73%) and PIK3CA (20%) mutations were most common, followed by KRAS mutations (11%) and amplifications (11%).
Conclusions
In this real‐world cohort, testing for HER2, dMMR and EBV status affected treatment decisions in 56% of the patients. Although most dMMR and EBV+ tumours had a PD‐L1 CPS ≥ 5, not all patients with a high probability of treatment response are identified. Based on these results, a stepwise diagnostic strategy is proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
ORCID-Profile: Karen van der Sluis
Förderung
- Dutch Cancer Society
- Dutch Ministry of Health, Welfare and Sport
- KWF Kankerbestrijding
- Ministerie van Volksgezondheid, Welzijn en Sport
Zitieren
APA
van der Sluis, K., van Sandick, J. W., van Dieren, J. M., Vollebergh, M. A., Grootscholten, C., van den Berg, J. G., Snaebjornsson, P., Hartemink, K. J., Veenhof, A. A. F. A., Chalabi, M., & Kodach, L. L. (2023). The clinical impact of testing for biomarkers in gastric cancer patients: a real‐world cohort. Histopathology. https://doi.org/10.1111/his.14869
Vancouver
van der Sluis K, van Sandick JW, van Dieren JM, Vollebergh MA, Grootscholten C, van den Berg JG, et al. The clinical impact of testing for biomarkers in gastric cancer patients: a real‐world cohort. Histopathology. 2023. doi:10.1111/his.14869
BibTeX
@article{vanderSluis2023,
author = {van der Sluis, Karen and van Sandick, Johanna W and van Dieren, Jolanda M and Vollebergh, Marieke A and Grootscholten, Cecile and van den Berg, José G and Snaebjornsson, Petur and Hartemink, Koen J and Veenhof, Alexander A F A and Chalabi, Myriam and Kodach, Liudmila L},
title = {The clinical impact of testing for biomarkers in gastric cancer patients: a real‐world cohort},
journal = {Histopathology},
year = {2023},
doi = {10.1111/his.14869}
}
EUVIMED